L
LTP
vs
S
S&P/ASX 300
Over the past 12 months, LTP has underperformed S&P/ASX 300, delivering a return of +1% compared to S&P/ASX 300's +4% growth.
Stocks Performance
LTP vs S&P/ASX 300
Performance Gap
LTP vs S&P/ASX 300
Performance By Year
LTP vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
LTR Pharma Ltd
Glance View
LTR Pharma is an Australian pharmaceutical company focused on turning known drugs into new delivery forms that are easier or faster to use. Its lead work is a prescription nasal spray for erectile dysfunction, based on a drug that is already well understood but delivered through the nose instead of a tablet. That puts the company in the drug development and commercialization part of the healthcare value chain, where the main job is to create, test, and bring a new formulation to market. The company’s customers are mainly men seeking treatment for erectile dysfunction, along with doctors, pharmacies, and healthcare partners that help prescribe, distribute, or commercialize the product. LTR Pharma makes money by selling its pharmaceutical products once approved and, like many small drug developers, may also earn revenue through licensing or partnership deals if larger commercial partners help bring the treatment to market. What makes the business different is that it is not trying to invent a brand-new medicine from scratch. Instead, it is trying to improve how an existing medicine is delivered, which can make development faster and more focused than building a completely new drug. That also means its success depends heavily on clinical testing, regulatory approval, and whether doctors and patients accept the nasal-spray format.
